Teva Pharmaceutical Industries (TEVA) Change in Acquisitions & Divestments (2009 - 2025)

Teva Pharmaceutical Industries (TEVA) has reported Change in Acquisitions & Divestments for 16 consecutive years, with $42.0 million the latest figure, recorded in Q4 2025.

• Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $42.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $82.0 million (up 105.0% YoY) and the FY2025 annual result came in at $42.0 million, up 5.0% from the prior year.
• Change in Acquisitions & Divestments rose to $42.0 million in Q4 2025 per TEVA's latest filing, from $40.0 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for TEVA reached as high as $107.0 million in Q2 2021 and fell as low as $1.0 million in Q3 2022.
• A 4-year average of $36.9 million and a median of $40.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2021 — Change in Acquisitions & Divestments surged 3466.67% — and 2022, when it slumped 97.2%.
• Year by year, Change in Acquisitions & Divestments stood at $19.0 million in 2021, then plunged by 94.74% to $1.0 million in 2022, then soared by 3900.0% to $40.0 million in 2024, then grew by 5.0% to $42.0 million in 2025.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $42.0 million, $40.0 million, and $1.0 million for Q4 2025, Q3 2024, and Q3 2022 respectively.